DaVita Inc. (DVA) Earnings Call Transcript & Summary
May 5, 2022
Earnings Call Speaker Segments
Joel Ackerman
executiveThanks. I want to welcome all of you to the conference call for our first quarter, and we're grateful that you keep taking an interest in the company. This is Joel Ackerman, serving as CFO and Treasurer, and with me today is Javier Rodriguez, who is our CEO. I'd ask you to keep in mind that we might make forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to all such statements, and those factors might lead actual results to differ materially from what the forward-looking statements describe. If you want more information about those risks and uncertainties, please look at the earnings press release for the first quarter along with our SEC filings, which include the annual report on Form 10-K filed most recently, plus any quarterly reports on Form 10-Q filed after that and other later filings we make with the SEC. The information we currently have forms the basis for our forward-looking statements, and except where the law requires it, we have no intention and take on no obligation to update them. Also, a reminder that some non-GAAP financial measures will be discussed on this call. You can find a reconciliation of those non-GAAP measures against the most comparable GAAP financial measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point, I'll hand the call over to Javier Rodriguez.
Javier Rodriguez
executiveThanks, Joel, and I appreciate everyone being on today's call. This is quite a moment, with our nation and the entire globe confronting a distinct set of one-off circumstances simultaneously. On the brighter side, since COVID infection rates have fallen, we're coming together and engaging more as communities and as a society. On the harder side, we're confronting fresh economic strains from inflation, supply channel limitations, and the tragic fallout of the Russia-Ukraine war. While our company navigates these difficulties, I believe it's essential to remember the reason DaVita exists: we're an organization centered on patients, delivering life-sustaining care to more than 240,000 individuals across 12 countries — which is why I'd like to open this call with a clinical highlight. As you're aware, enhancing a patient's experience in managing kidney disease has been one of our main areas of focus. A way to accomplish that involves targeted work to cut down how much time patients under our care spend in the hospital. Through our new integrated care partnerships, we've been expanding our care models and are observing initial outcomes of double-digit % decreases in hospital time, which is truly wonderful for our patients and for the healthcare system. These outcomes match what we anticipated. The gains come mainly from our care management, our clinical interventions, and our emphasis on patient care quality. Fewer hospitalizations means a better quality of life for our patients and more healthy days at home enjoying what they love with the people they love. We feel optimistic about these initial outcomes and will keep seeking ways to enhance our patients' quality of life. Now, let me shift to how we performed in the first quarter. During Q1, we generated operating income of $338 million and earnings per share of $1.61. Operating income fell on a sequential basis, largely because of normal seasonal patterns, ongoing volume pressures related to COVID, and greater wage costs. The Omicron variant's mortality rate has been much lower than earlier variants, yet the enormous number of cases led to an estimated excess patient mortality of roughly 2,100 during the first quarter. As a result, our treatment volumes dropped relative to the previous quarter. Fortunately, patient infections and mortality rates have fallen across the last couple of months, in line with national trends, and we haven't yet observed a meaningful impact from new subvariants. So we're starting to see encouraging trends in treatment volumes during both March and April; regarding staffing, as we've noted before, the labor market remains difficult for us. Compared with a year ago, our first quarter field labor expense rose by more than 6%. That rise stems from a combination of merit increases above the usual level, greater incentive pay, more reliance on contract labor, and reduced productivity, mainly because of higher training costs and inefficient staffing tied to cohorting COVID patients. Even though we're encouraged by signs that it's getting easier to staff our clinics, we still anticipate labor costs climbing more than usual compared to last year throughout 2022. Given all of this, our results are, in our view, more apt to land in the lower half of the guidance range we set for 2022; that said, because labor costs and COVID create so much environmental uncertainty, certain scenarios could put us either above or below that. As we look toward 2023 and past it, we're bracing for wage rates to keep rising faster than they have historically on average. Offsetting that will require us to keep proving we can innovate on cost; we've already pinpointed several chances to save, which should help blunt these inflationary forces. Among them: savings tied to a new ESA contract, efficiencies in G&A, better use of capacity, optimization of clinical operations, and improvements in procurement; we anticipate these savings beginning to show up in 2023, and reaching their full run rate by 2025. Combined with an outlook for larger rate increases down the road from government and private payers, we think these expected savings can keep us on track to hit our long-term adjusted operating income growth of 3%-7% along with adjusted earnings per share growth of 8%-14%. I'll close my prepared remarks by offering a few thoughts about our Integrated Kidney Care, or IKC, business. As we discussed at our Capital Markets Day, we still see considerable promise in our IKC business. To begin, delegated patient volumes remain robust and match our original modeling, and could even exceed it over the coming 12 months. We're where we expected to be on ESKD member growth through new payer partnerships, and we're running ahead of plan when it comes to new CKD payer partnerships, since payers see how well we work with physicians to manage this patient population. Next, the savings available to us might exceed what we first projected, thanks to strong engagement from nephrologists and the roughly 10% bump in the 2023 MA rate that was recently announced. Third, the roster of nephrologists we partner with in value-based care has grown; we've entered a new value-based partnership involving more than 1,800 nephrologists nationwide, and over 600 nephrologists are now on an integrated CKD electronic health record. Finally, our confidence in the clinical model remains intact, and it's now starting to run at scale. With that, I'll hand things to Joel, who will go deeper into our financial performance and outlook.
Joel Ackerman
executiveThanks, Javier. First off, I want to give you a bit more detail on the numbers we reported for the first quarter. The main factor behind the roughly $50 million drop in operating income compared with Q4 was seasonal items. First, there were 2 fewer treatment days in Q1, and that worked out to approximately 185,000 fewer treatments. Second, revenue takes a seasonal hit because patient coinsurance and deductibles are higher. And third, payroll tax costs are elevated in Q1. Now let me move to what's driving operating income beneath the surface. U.S. dialysis treatments per day came in at about 2,000 lower in Q1 2022 than in Q4 2021, a decline of 2.2%, largely due to excess mortality associated with COVID late in Q4 and through Q1. Higher rates of missed treatments in Q1, a consequence of the Omicron surge, added to the pressure pushing treatments down. On a quarter-over-quarter basis, revenue per treatment decreased by approximately $0.35, mainly a reflection of greater seasonal coinsurance and deductibles, which was mostly offset by 2022 increases in the Medicare fee-for-service rate as well as continued gains in both MA and commercial mix. Patient care cost per treatment increased $4.49 quarter-over-quarter, due primarily to higher wage rates and to lower treatment volume being spread across fixed expenses at our centers. G&A expenses were down about $26 million quarter-over-quarter, largely because of the seasonal pattern in our G&A spending. In the IKC business, our Q1 operating loss was in line with expectations, and we continue to invest in growth. We remain on track to make the incremental $50 million investment in that business this year. During Q1, we repurchased 2.1 million shares of our stock, and since the quarter ended we've bought back an additional 800,000 shares. Now, on to the rest of 2022: in Q2, we expect operating income to rebound as the Q1 seasonal items fade, partially offset by the reduction and eventual full elimination of sequestration relief in Q3 and Q4. In Q3, we anticipate the bulk of the ballot cost impact will be felt. Finally, Q4 should improve sequentially, with ballot-related costs much lower. Let me turn now to our 2023 outlook. As we shared at our Capital Markets Day, we see 2022 as a transition year; we expect operating income to rebound in 2023, driven by core business growth, a reversal of certain COVID headwinds, no contribution toward the industry's fight against California ballot initiatives, and momentum in our IKC business. At our Capital Markets Day, we estimated that the operating income rebound from 2022 to 2023 would land somewhere between $250 million and $400 million. Our updated 2023 outlook hinges on three of those underlying drivers. First, we now expect sustained cost pressure on wages and from inflation that wasn't included in our earlier guidance. The magnitude of those pressures will depend largely on how the labor environment develops over the next several quarters. We're bracing for another 12 months of wage pressure in 2023. That increase will land a couple of percentage points above the growth we've seen historically, but it should be less severe than what we're facing this year. We believe larger RPT increases from Medicare fee-for-service, plus other payers, will offset part of those added costs. Still, most of our commercial and MA book will likely need more time to catch up, because of our multi-year contracts. Second, as Javier noted, we've identified several cost-saving opportunities that we expect will begin contributing in 2023. We don't anticipate meaningful CapEx associated with those projects, but we could incur some one-time expenses tied to certain efforts in 2022, 2023, and potentially 2024. Those non-recurring expenses are excluded from our guidance. Finally, on COVID. Our inability to predict how the pandemic will evolve continues to create substantial variability in our projections. What we shared about 2023 at Capital Markets Day assumes a scenario in which excess mortality from COVID would be negligible, with growth accelerating beginning in 2023. As Javier said, even though treatment volumes have recently improved, we remain cautious about future surges. If surges persist this year, if COVID deaths continue, and if the virus remains endemic, then COVID's impact on our forecast could shift from a tailwind to a headwind in 2023. Bringing this all together, while it's still early to give full guidance for 2023, particularly in such a dynamic environment, we currently believe that if COVID largely recedes as a driver of elevated mortality this year, we feel good about an OI increase in the range of $240 million to $400 million versus 2022. If COVID remains a headwind this year and into 2023, we would still expect a strong rebound, but we can't quantify it given the uncertainty. Operator, please open the line for Q&A.
Kevin Fischbeck
analystOkay, sounds good, thank you. So, regarding the first quarter, you came in below consensus by a fair margin, yet you're essentially reiterating your outlook at the lower end of that range, which suggests the remaining months will unfold as you originally anticipated, even though it seems these cost programs won't provide any benefit until the following year. I'm just trying to understand why the first-quarter strain won't affect the second half of the year the same way it affected Q1.
Joel Ackerman
executiveYes, Kevin. The first quarter was largely shaped by two seasonal factors that together created roughly $60 million of pressure on OI. The first has to do with treatment days. During that quarter, treatment days were down by 2, and that accounts for approximately half of the effect. The second factor involves seasonal patterns tied to co-insurance and deductible, and that contributes roughly another $30 million. Once you remove those items, there are various other elements that came through during the quarter which will essentially be puts and takes across the remainder of the year. Strip out that seasonality, and I believe that covers most of the difference.
Kevin Fischbeck
analystSo maybe the better way to frame it is whether the first quarter landed where you figured it would. Since those are both seasonal patterns you'd already have been aware of, are you simply telling us that analysts failed to account for them properly? Or is there something else?
Joel Ackerman
executiveThe larger portion, I'd say, is that. Even so, Q1 fell short of our forecast, mainly on the volume side. Deaths ran above what we had modeled, and though our full-year assumption on mortality isn't shifting, it showed up sooner than we'd anticipated. The rate of missed treatments also exceeded our projection. Normally the first quarter brings a bigger missed treatment rate thanks to flu patterns, yet it climbed even beyond what we'd have guessed, and COVID is chiefly responsible for that.
Kevin Fischbeck
analystAll right. Regarding the possibility for rate improvement across the coming several years to counterbalance those expenses, I suppose, what's the state of the commercial landscape? What I mean is, you folks have discussed net rate updates that are comparatively modest, historically speaking. So that makes me question whether you believe you genuinely possess negotiating leverage with commercial payers as time goes on. What's your view on that capability — when inflation rises, do you actually hold that leverage, or should we continue to assume that wage or overall rate increases will likely be lower than what you expect cost growth to be, even if it eventually begins to close the gap?
Javier Rodriguez
executiveKevin, it's Javier here. I appreciate the question. The brief response is that it's too soon to say, since, as we've shared with you, our contracting is comprehensive, and the majority of those agreements span multiple years. In any particular year, only about 15%-20% or so is probably up for negotiation; it's slightly early to determine. As for your point about who holds leverage, the truth is, as you're aware, payers possess greater market share than we do in every individual market. It's a productive discussion. What everyone is attempting to do right now is determine whether we can get our incentives aligned in order to secure more forward-looking contracts that reduce costs for the system as a whole. It's a bit early to determine. Plenty is happening on the revenue side, as you know well, given how long you've followed us, because naturally there's mix and rate along with numerous other factors. Our ongoing view is that for the foreseeable future at minimum, yield will stay within that 1%-2% range.
Kevin Fischbeck
analystOkay. For my final question, then. I suppose the RPT has gotten a boost from the movement toward MA. Where would you say we stand in that transition? We all enjoy the baseball comparison, I think. Which inning does that put us in? Should we look for comparable increases during 2023 or 2024, or have we mostly reached a stable level at this point? Thank you.
Javier Rodriguez
executiveYes. I can't say which inning that would be, but in my view the largest leap is already behind us. We moved from clearly below average in the market to approximately even with it; our new patients keep picking MA more often than Medicare, so our expectation is that this simply keeps becoming more incremental, though a bit above the MA market as a whole.
Kevin Fischbeck
analystAll right, thank you.
Javier Rodriguez
executiveI appreciate it, and I'd add that we're looking at somewhere in the neighborhood of $8 million to $9 million.
Justin Lake
analystThank you. Perhaps we could spend another moment on the revenue we get for each treatment. According to what you mentioned, seasonal effects related to co-pays and similar items cost you roughly $30 million. On a per-treatment basis, that works out to slightly more than $4. Sequentially, revenue per treatment would have risen by around 1%. Considering the Medicare rate changes, plus MA, plus your comment that the commercial mix improved, is there another factor affecting revenue per treatment that we haven't accounted for beyond that?
Joel Ackerman
executiveNo, Justin, you aren't overlooking anything. The items you identified are the correct ones, and they approximately offset one another. A handful of minor additional elements exist, since some degree of fluctuation is always present, but nothing further is involved in this situation.
Justin Lake
analystCould you refresh my memory on the Medicare rate once more, compared with a year earlier?
Joel Ackerman
executiveThat figure sits in the high ones — somewhere between 1.7% and 1.9%.
Justin Lake
analystRight; that by itself would have given you, you know, according to my calculations, you know, which are a bit imprecise, but that by itself would have given you slightly more than 1%. On top of that, you mentioned that the commercial mix improved, so that would have given you, you know, your $4 back. The commercial mix is better, you said. Could you provide that figure for us? How did commercial mix perform sequentially, and how did MA penetration perform sequentially?
Joel Ackerman
executiveYeah. I believe the government rate figure, you're somewhat overestimating. You have to factor in some Medicare bad debt there. There are some mix changes within government. There are flu shots. There's a bit of noise in there, which is, I think, stopping your numbers from ticking and tying.
Justin Lake
analystAll right. Could you share how the Medicare Advantage and commercial mix performed? Which quarter are we talking about — the first one?
Joel Ackerman
executiveFor that quarter, MA mix landed at slightly below 45%, while commercial mix stood at just shy of 10.5%.
Justin Lake
analystDuring the fourth quarter, what did those figures come to? Are they available to you?
Joel Ackerman
executiveJust a moment. The Medicare Advantage proportion stood at 39%, while the commercial figure came in at 10.38%.
Justin Lake
analystAll right. So, circling back to, you know, how earnings moved quarter over quarter, when you mentioned that the second quarter would bounce back.
Joel Ackerman
executiveMy apologies — the figure I gave you was incorrect. For the fourth quarter, MA came in at 42%.
Justin Lake
analystAll right, thank you for that. You mentioned the second quarter will bounce back following Q1, which had a few, you know, seasonal challenges. When you say rebound, are you talking about returning to something like the fourth quarter? We're just trying to align consensus and, you know, get models matching what you have in mind, at minimum. Will it be roughly comparable to the fourth quarter? Does bouncing back mean reaching that Q4 level, or going higher than it? Any detail you can give us on that would help.
Joel Ackerman
executiveYeah.
Justin Lake
analystWhat's the percentage?
Joel Ackerman
executiveI really don't want to begin handing out guidance on a quarterly basis, so that's a question I'm going to avoid.
Justin Lake
analystAlright. You provided a figure regarding wages. My recollection is it was $100 million-$125 million that you'd added beyond what's normal in the OI guidance. Would you like to share a revised figure for that?
Joel Ackerman
executiveYes. Our current thinking, I believe, is that we're at the upper portion of that range. Q1 was roughly 6% higher than the same period last year, and I think you can base a model on approximately $3.5 billion; at present we're probably anticipating slightly under 6%. For the entire year, we're now expecting about six, perhaps a touch more than that. That would produce a figure in line with the top of that range.
Justin Lake
analystAll right, and then the final item: many of us reviewed the rates released for hospitals and we're puzzled about the reason, you know, that a portion of this staffing cost pressure plus broader inflation appeared not to show up. I realize your team devotes considerable effort to conversations with CMS. From what I understand, your rates haven't been published at this point, but what's the timing — when will that begin happening? Do you expect that in dialysis rates, say, for 2023, we'll begin to witness CMS starting to build in a certain amount of inflation there?
Joel Ackerman
executiveYes. Look, my sense is the figure for 22 came in above typical levels. You know, I'm not certain we possess much greater visibility than all of you regarding the cause, but I'd say treating inflation as a reasonable premise makes sense. The preliminary rate covering 2023 won't be visible to us until late June or early July.
Justin Lake
analystOkay.
Javier Rodriguez
executiveRemember-
Justin Lake
analystOkay.
Javier Rodriguez
executiveJustin, that formula isn't quite as simple as it might seem. You'd assume they'd take either historical or projected data that had actually been customized to match our particular financial picture. That isn't what happens. What they actually do is pull a basket update, run some forward-looking modeling, then layer on a productivity index of some sort, and that's how the figure gets produced. It's hospital labor-driven, and it's 2 years old, so you're going to see somewhat of a delay — that's the whole point.
Justin Lake
analystAh, that's the crux of it. All right; this is the area I was hoping to understand a bit better, Javier. Thanks for that. What you're telling me is that whatever inflationary pressure Medicare is factoring in — whether it's on wages or whatever wage inflation is occurring — traces back to two years ago. The rate for 2023 reflects 2021 inflation.
Javier Rodriguez
executiveThat's how we understand it, Justin.
Justin Lake
analystFine. Understood, everyone. I appreciate the additional detail.
Javier Rodriguez
executiveYou're welcome.
Joel Ackerman
executiveMissy? Operator?
Pito Chickering
analystI'd like to ask some questions. Looking back at the first quarter treatments, I get it — higher mortality, plus those skipped treatments, you know, seasonality. Earlier, your guidance for 2022 treatments was growth of about 1%-1.5%. So, I guess, has anything changed in that assumption? And then, could you quantify for us the treatments you saw in March and April, and what ought we to model for sequential treatment growth going into 2Q?
Joel Ackerman
executiveYeah; our thinking is that year-over-year treatment growth is going to be down compared with the roughly 0.5%-1% we mentioned previously. Somewhere nearer to zero is now the better way to model it, I'd say. Across the quarter, we did witness a dramatic decline. This is from memory, but the figures were something above 1,500 in January, a few hundred in February, and then 150 in March, I believe. The excess mortality figure did fall significantly. As for modeling Q2, again, there's a lot of uncertainty. Should historical patterns persist, you'd anticipate treatment per day growth in Q2 and the next surge actually arriving in the summer. Whether historical patterns will persist is not clear.
Pito Chickering
analystI'm going to let you pick whatever range you like, based on what you're observing in your treatments or how they're trending, I suppose, in April, on a sequential basis — should that be rising by 50 basis points between 1Q and 2Q? There are additional treatment days, sure, but at the same time you've got excess mortality running differently than usual, not around. I suppose you could just help us put a number on treatment growth in 2Q.
Joel Ackerman
executiveYeah. First off, I would suggest you model treatments per day, since you'll end up with a cleaner figure using the count of treatment days. I believe I can say with comfort that it will increase. Whether I'm prepared to put a number on it yet, I'm not sure.
Pito Chickering
analystAll right. Regarding what Justin asked about treatment revenue, there are, as you know, quite a few variables at play here, including mix and COVID, among other things. Typically when we move from 1Q to 2Q, we tack on roughly $5-$6 relative to the first quarter. That brings you to approximately $367 in 2Q revenue per treatment. Does that reflect the correct way to look at it?
Joel Ackerman
executiveFor an ordinary year, I'd say your figure is accurate. Keep in mind that during Q1 we receive roughly $17 million in sequestration suspense dollars; for Q2 that amount is reduced by half; as a consequence, we'll give up, let's say, $8 or $9 million dollars in revenue. That works out to a cost to us of slightly over $1 per treatment.
Pito Chickering
analystAlright, so for the second quarter, roughly 366 is the way to think about it, then.
Joel Ackerman
executiveYeah, that's a reasonable place to begin, I'd say.
Pito Chickering
analystAll right. So for my final question, regarding the IKC group, are you receiving the true-ups from your managed care partners for 2021? I'm just wondering if you could share some insight into, well, how did those patients perform in 2021 relative to what you expected? Any details on the pattern of losses would help. For the patients you had, whether they came on board with you in the first quarter of 2021 or in the fourth quarter of 2021. Yeah, I suppose, well, in what way did those losses shift? And then my last thing is, I noticed your IKC losses dropped sequentially to $37 million in 1Q, down from $300 million in the fourth quarter. You know, I figured that number would have risen given that, well, you're adding more patients to the platform. If you could pull all of that together for me, that would be wonderful.
Joel Ackerman
executiveYeah. To start with the 2021 true-ups, those will arrive much later in the year. We haven't really observed much regarding that, so we have no reason to think anything is significantly different; as for the IKC losses, they're down a little bit in Q1. I believe we received some payments in Q4 of last year, but it's really mostly just normal variability. I don't think there's anything big to call out there.
Pito Chickering
analystRight. For the previous year, when do your managed care partners provide those true-ups?
Joel Ackerman
executiveThat differs from one partner to another, though my expectation is that the majority will come during the latter half of the year. Keep in mind that claims need a considerable amount of time to run out before you can genuinely determine what those figures are.
Pito Chickering
analystUnderstood. One final check on that. So you've provided figures covering the bottom end of the 2022 guidance range, yet the $240-$400 figure still stands. Should we therefore take it that our 2023 models ought to sit near $1,875 for 2023?
Joel Ackerman
executiveCorrect. I would calculate the $250-$400 using the fresh figure we just handed you. To be honest, I'm working this out mentally right now. Your $1,875 estimate strikes me as being in the correct ballpark.
Pito Chickering
analystAlright, that's wonderful. Many thanks, everyone.
Javier Rodriguez
executiveAlright, I appreciate it. So, a few final remarks are how I'd like to wrap up. The results we deliver for patients, along with gains in how well they live, keep driving the 65,000 people who work here. Given both COVID and the unpredictability of inflation, our near-term view stays considerably less clear than it normally would be — especially, as we went through, when it comes to volume and wage rates. A great deal of effort is going into innovating and bringing down our cost structure so that some of these unknowns are softened, and our confidence remains very strong that the capabilities and investments we are putting in place will set us up to outperform in the years to come. I'm grateful for the time you've given and for your investment in DaVita. Take care.
Operator
operatorThat brings us to the end of today's call. You're welcome to hang up now, and we appreciate your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.